Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.31 (0.77%)
Data as of 09/26/16 10:39 a.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
09/21/16The Medicines Company Awarded up to $132 Million to Develop Portfolio of New Antibiotics Targeting Drug-Resistant Infections under Strategic Partnership with BARDA
—Provides up to $132 million to support development of the Company’s leading pipeline of antibiotics targeting drug-resistant bacteria, including the ongoing development of CARBAVANCE® (meropenem-vaborbactam)— —First portfolio-based strategic partnership between the Biomedical Advanced Research and Development Authority (BARDA) and a U.S. headquartered company— —Strategic partnership evidences the leadership position of The Medicin... 
Printer Friendly Version
08/30/16The Medicines Company Provides Update on Dyslipidemia Programs
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 30, 2016-- The Medicines Company (NASDAQ:MDCO) today provided an update on its clinical dyslipidemia research programs for MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor). MDCO-216. A planned, interim analysis of the first 40 randomized patients completing treatment in the MILANO-PILOT study of MDCO-216 has been reviewed by the Independent Data Monitoring Committee (IDM ... 
Printer Friendly Version
07/27/16The Medicines Company Reports Second-Quarter 2016 Business and Financial Results
— Advanced potential blockbuster R&D programs — — Completed divestiture of non-core cardiovascular assets — — Refinanced substantial portion of near-term debt obligations — — Transactions significantly strengthen balance sheet and provide valuable strategic and operational flexibility — PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 27, 2016-- The Medicines Company (NASDAQ:MDCO) today announced its business and financial resul... 
Printer Friendly Version
07/18/16The Medicines Company to Announce Second Quarter Financial Results on July 27, 2016
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 18, 2016-- The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for July 27, 2016 at 8:30 a.m. Eastern Time to discuss second quarter financial results and operational developments. The conference call will be available via phone and webcast. The dial-in information is listed below: Domestic Dial In: + 1 (877) 359-9508 International Dial In: + 1 (224) 357-23... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.